Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-05-31

Study Completion Date

2010-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies

NCT00914849

Hematologic Neoplasms

COMPLETED PHASE2

Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma

NCT00733824

Lymphoma, Non-Hodgkin Hodgkin Disease

COMPLETED PHASE1/PHASE2

An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers

NCT00322127

Healthy Volunteers

COMPLETED PHASE1

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

NCT00544115

Chronic Myeloproliferative Disorders Graft Versus Host Disease Leukemia +5 more

ACTIVE_NOT_RECRUITING PHASE2

Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

NCT04709458

Myelofibrosis Acute Myelogenous Leukemia

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia, Myeloid, Acute Leukemia, Myelogenous, Chronic Leukemia, Lymphoblastic, Acute Lymphocytic Leukemia, Chronic Myelodysplastic Syndromes Multiple Myeloma Lymphoma, Non-Hodgkin Hodgkin Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subcutaneous (SC) Treatment Plan - Donor

* Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis
* If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3.

Group Type ACTIVE_COMPARATOR

AMD3100

Intervention Type DRUG

Intravenous (IV) Treatment Plan - Donor

* Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis
* Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis
* If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3.

Group Type EXPERIMENTAL

AMD3100

Intervention Type DRUG

Recipients

* Conditioning Regimen

* Cyclophosphamide 60mg/kg/day on Days -3 and -2
* TBI 550cGy on Day -1
* GVHD prophylaxis

\*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100
* PBSC transplant on Day 0

Group Type OTHER

Stem Cell Transplant

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMD3100

Intervention Type DRUG

Stem Cell Transplant

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Plerixafor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Donor criteria:

* Donor is 18 to 70 years of age inclusive
* If female and of child-bearing age, must be:

* non-pregnant,
* not breast feeding and
* using adequate contraception
* Donor is a 6/6 HLA-matched sibling willing to donate peripheral blood stem cell for transplant
* Donor must be willing to provide written informed consent.
* Adequate cardiac function with no history of congestive heart failure and no history of atrial fibrillation or ventricular tachyarrhythmia.
* Adequate renal function as defined by a serum creatinine clearance of ≥75% of normal (Cockcroft-Gault equation)
* Adequate hepatic function as defined by a total bilirubin \<2x normal or absence of hepatic fibrosis/cirrhosis
* Adequate neurologic function as defined by:

* No evidence of a severe central or peripheral neurologic abnormality.
* No history of cerebrovascular accident or seizure disorder requiring anticonvulsant medication
* Must be HIV-1 \& 2 antibody, HIV-1 antigen, and HTLV-I \& II antibody sero-negative, by FDA licensed test.
* Must have an ECOG performance status of 0 or 1
* Must demonstrate ability to be compliant with study regimen.
* Must not have an active infection at the time of study entry
* Not have active alcohol or substance abuse within 6 months of study entry
* Not currently enrolled in another investigational agent study
* Not have any medical condition, which, in the opinion of the clinical investigator, would interfere with his/her evaluation

Recipient criteria:

* 18 to 65 years of age inclusive
* Willing and has a 6/6 HLA-matched sibling willing to donate PBSC for transplant
* Provide signed informed consent
* If female and of child-bearing age, must be:

* non-pregnant,
* not breast feeding, and
* using adequate contraception

Patient must have one of the following diagnoses:

* AML in 1st or subsequent remission or in relapse
* ALL in 1st or subsequent remission or in relapse
* MDS and intermediate 1 or 2, or high risk by the International Prognostic Scoring System
* CML in accelerated or second chronic phase
* NHL or HD in 2nd or greater complete remission, partial remission,or refractory relapse
* CLL Rai Stage 2-4, failing at least 2 prior regimens
* MM Stage 2-3
* Adequate cardiac function with a left ventricular ejection fraction ≥ 40%
* Adequate pulmonary function defined as:

* No severe or symptomatic restrictive or obstructive lung disease, and
* formal pulmonary function testing showing an forced expiratory volume at 1 second (FEV1) ≥50% of predicted and a diffusion capacity of the lung for carbon monoxide (DLCO) ≥40% of predicted, corrected for hemoglobin
* Adequate renal function as defined by a serum creatinine clearance of ≥75% of normal (Cockcroft-Gault equation)
* Adequate hepatic function as defined by a total bilirubin \<2x normal or absence of hepatic fibrosis/cirrhosis
* Adequate neurologic function as defined by no evidence of a severe central or peripheral neurologic abnormality. Patients with a history of previous central nervous system tumor involvement are eligible provided they are without symptoms or signs and the CNS is now free of disease on lumbar puncture and CT scan of the brain
* No evidence of active infection at the time of the transplant preparative regimen or at the time of transplantation
* Patient must be HIV-1 \& 2 antibody, HIV-1 antigen, and HTLV-I \& II antibody sero-negative, by FDA licensed test
* ECOG performance status of 0 or 1
* Must demonstrate ability to be compliant with medical regimen
* Not have active alcohol or substance abuse within 6 months of study entry
* Not be concurrently enrolled on another study involving an investigational agent
* Not have any medical condition, which, in the opinion of the clinical investigator, would interfere with the evaluation of the patient

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No